---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-066968"
form_type: "8-K"
ticker: "INGN"
cik: "0001294133"
company_name: "Inogen Inc"
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:42:24.642469+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inogen reports FY2025 revenue $348.7M (+3.9%); net loss narrows to $22.7M; first positive adj. EBITDA in four years

## Summary
- Revenue $348.7M (+3.9% YoY); net loss $22.7M improved from $35.9M loss in 2024.
- Adjusted EBITDA turned positive at $2.7M (vs -$9.5M in 2024); Q4 adj. EBITDA -$1.7M improved from -$3.6M.
- Cash and equivalents $120.9M with zero debt; Board authorized $30M share repurchase program through Dec 2027.
- International POC sales grew 18.4% in 2025; introduced new products Voxi 5, Aurora CPAP masks, Simeox airway clearance.
- Total gross margin 44.2% in 2025 vs 46.1% in 2024 due to channel mix.

## SEC filing metadata
- accession: 0001193125-26-066968
- form_type: 8-K
- ticker: INGN
- cik: 0001294133
- company_name: Inogen Inc
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1294133/000119312526066968/0001193125-26-066968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1294133/000119312526066968/ingn-20260220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-066968
- JSON: https://secwatch.observer/filing/0001193125-26-066968.json
- Plain text: https://secwatch.observer/filing/0001193125-26-066968.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.